NeuroMetrix Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>NE</div>
NURO -- USA Stock  

USD 4.18  0.13  3.21%

NeuroMetrix Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.95. Book Value per Share is expected to rise to 2.66 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (3.9 M). This short post will outline NeuroMetrix as a possible investment alternative for your portfolios. We will provide a perspective on NeuroMetrix future direction.
Published over three weeks ago
View all stories for NeuroMetrix | View All Stories
Are NeuroMetrix (NASDAQ:NURO) institutional investors starting to hold back?
About 2.0% of NeuroMetrix shares are owned by institutional investors. Insiders ownership of NeuroMetrix refers to the amount of NeuroMetrix equity owned by NeuroMetrix officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of NeuroMetrix, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as NeuroMetrix. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for NeuroMetrix

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of NeuroMetrix's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of NeuroMetrix in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as NeuroMetrix. Your research has to be compared to or analyzed against NeuroMetrix's peers to derive any actionable benefits. When done correctly, NeuroMetrix's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in NeuroMetrix.

How important is NeuroMetrix's Liquidity

NeuroMetrix financial leverage refers to using borrowed capital as a funding source to finance NeuroMetrix ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NeuroMetrix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NeuroMetrix's total debt and its cash.

How NeuroMetrix utilizes its cash?

To perform a cash flow analysis of NeuroMetrix, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NeuroMetrix is receiving and how much cash it distributes out in a given period. The NeuroMetrix cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NeuroMetrix Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (4.49 Million)

Acquisition by Van Avermaete David of 5000 shares of NeuroMetrix subject to Rule 16b-3

Legal trades by NeuroMetrix insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NeuroMetrix insider trading alert for grant of stock option (right to buy common stock) by Van Avermaete David, the corporate stakeholder, on 15th of January 2021. This event was filed by Neurometrix Inc with SEC on 2021-01-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at NeuroMetrix

NeuroMetrix is displaying above-average volatility over the selected time horizon. Investors should scrutinize NeuroMetrix independently to ensure intended market timing strategies are aligned with expectations about NeuroMetrix volatility.

Margin Breakdown

EBITDA Margin(0.42)
Gross Margin0.33
Profit Margin(0.44)

Another 3 percent rise for NeuroMetrix

NeuroMetrix latest potential upside surges over 11.69. As of the 24th of December, NeuroMetrix secures the Mean Deviation of 3.85, downside deviation of 4.15, and Risk Adjusted Performance of 0.1972. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeuroMetrix, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for NeuroMetrix, which can be compared to its peers in the industry. Please verify NeuroMetrix jensen alpha and semi variance to decide if NeuroMetrix is priced some-what accurately, providing market reflects its recent price of 3.61 per share. Given that NeuroMetrix has jensen alpha of 1.07, we recommend you to check NeuroMetrix's last-minute market performance to make sure the company can sustain itself at a future point.

The Current Takeaway on NeuroMetrix Investment

Whereas many other companies under the medical instruments & supplies industry are still a bit expensive, NeuroMetrix may offer a potential longer-term growth to institutional investors. To sum up, as of the 24th of December 2020, we believe that NeuroMetrix is currently overvalued with high odds of financial turmoil in the next two years. Our final 30 days buy-hold-sell advice on the company is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NeuroMetrix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com